Production of interleukin-10 by human bronchogenic carcinoma - PubMed (original) (raw)

Production of interleukin-10 by human bronchogenic carcinoma

D R Smith et al. Am J Pathol. 1994 Jul.

Abstract

Interleukin-10 (IL-10) is a recently characterized cytokine with suppressive activity against various aspects of the cellular immune response. Our laboratory has previously demonstrated that another anti-inflammatory cytokine, IL-1 receptor antagonist (IRAP) is produced and secreted by human bronchogenic carcinomas. We speculated that tumor production of IRAP may mitigate host responses and confer increased tumor viability. In this study, we investigated the capacity of human bronchogenic tumors to produce IL-10 as another possible mechanism to attenuate host defenses. We found increased levels of antigenic IL-10 in tissue homogenates of human bronchogenic carcinomas compared with normal lung tissue (13.69 +/- 2.87 versus 5.84 +/- 0.84 ng/mg total protein). Immunohistochemical staining of tumors illustrate primary localization of antigenic IL-10 to individual tumor cells. Analysis of supernatants of several unstimulated human bronchogenic cell lines in vitro demonstrated the ability of tumor cells to constitutively produce IL-10. Functional studies of mononuclear cells, cultured in the presence of conditioned medium from a bronchogenic cell line, demonstrated their increased tumor necrosis factor and IL-6 production with the addition of neutralizing antibodies to IL-10. These findings demonstrate that human bronchogenic carcinomas elaborate functional IL-10, which may significantly impair immune effector cell function and enable the tumor to evade host defenses.

PubMed Disclaimer

Similar articles

• The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma.
  Smith DR, Kunkel SL, Standiford TJ, Chensue SW, Rolfe MW, Orringer MB, Whyte RI, Burdick MD, Danforth JM, Gilbert AR, et al. Smith DR, et al. Am J Pathol. 1993 Sep;143(3):794-803. Am J Pathol. 1993. PMID: 8362978 Free PMC article.
• Human non-small cell lung cancer cells express a type 2 cytokine pattern.
  Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura K, Modlin R, Wollman J, Dubinett SM. Huang M, et al. Cancer Res. 1995 Sep 1;55(17):3847-53. Cancer Res. 1995. PMID: 7641203
• Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma.
  Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD, Wilke CA, Strieter RM. Smith DR, et al. J Exp Med. 1994 May 1;179(5):1409-15. doi: 10.1084/jem.179.5.1409. J Exp Med. 1994. PMID: 7513008 Free PMC article.
• Class I major histocompatibility complex antigens and tumor ploidy in breast and bronchogenic carcinomas.
  Redondo M, Concha A, Ruiz-Cabello F, Morell M, Esteban F, Talavera P, Garrido F. Redondo M, et al. Cancer Detect Prev. 1997;21(1):22-8. Cancer Detect Prev. 1997. PMID: 9043759
• Ein kleiner Einstieg zu Diagnostik und Prädiktion des Lungenkarzinoms.
  Soltermann A. Soltermann A. Ther Umsch. 2017 Sep;74(4):157-164. doi: 10.1024/0040-5930/a000899. Ther Umsch. 2017. PMID: 28950769 Review. German. No abstract available.

Cited by

• Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.
  Zur RT, Adler G, Shamalov K, Tal Y, Ankri C, Cohen CJ. Zur RT, et al. Exp Suppl. 2022;113:253-294. doi: 10.1007/978-3-030-91311-3_9. Exp Suppl. 2022. PMID: 35165867
• Low Preoperative albumin-to-globulin ratio Predict Poor Survival and Negatively Correlated with Fibrinogen in Resectable Esophageal Squamous Cell Carcinoma.
  Li XH, Gu WS, Wang XP, Lin JH, Zheng X, Zhang L, Kang T, Zhang ZX, Liu WL. Li XH, et al. J Cancer. 2017 Jul 2;8(10):1833-1842. doi: 10.7150/jca.19062. eCollection 2017. J Cancer. 2017. PMID: 28819381 Free PMC article.
• Molecular and Cellular Mechanisms of Antitumor Immune Response Activation by Dendritic Cells.
  Markov OV, Mironova NL, Vlasov VV, Zenkova MA. Markov OV, et al. Acta Naturae. 2016 Jul-Sep;8(3):17-30. Acta Naturae. 2016. PMID: 27795841 Free PMC article.
• Tumor-derived factors modulating dendritic cell function.
  Zong J, Keskinov AA, Shurin GV, Shurin MR. Zong J, et al. Cancer Immunol Immunother. 2016 Jul;65(7):821-33. doi: 10.1007/s00262-016-1820-y. Epub 2016 Mar 16. Cancer Immunol Immunother. 2016. PMID: 26984847 Free PMC article. Review.
• Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.
  Perng P, Lim M. Perng P, et al. Front Oncol. 2015 Jul 6;5:153. doi: 10.3389/fonc.2015.00153. eCollection 2015. Front Oncol. 2015. PMID: 26217588 Free PMC article. Review.

References

1. 1. Biochem Biophys Res Commun. 1989 Nov 30;165(1):349-54 - PubMed
2. 1. J Immunol. 1991 Dec 1;147(11):3815-22 - PubMed
3. 1. J Immunol. 1986 Apr 1;136(7):2348-57 - PubMed
4. 1. J Immunol. 1987 Aug 15;139(4):1142-7 - PubMed
5. 1. J Exp Med. 1989 Dec 1;170(6):2081-95 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information